With news the US Food and Drug Administration (FDA) has accepted Mesoblast’s (ASX: MSB) Biologics License Application, a bump in the share price might be on the horizon. So, is now the moment to take a punt on the prospect of a positive outcome? Or could regulatory scrutiny push this company towards penny stock status, given the critical importance of FDA decisions? In the biotechnology and pharmaceutical industries, few events are as eagerly awaited as an FDA approval. Understanding the impact of such approvals is crucial when deciding whether to invest. Securing FDA approval signifies a stro…